Bilaal.Raja
Company record

BIOA  BioAge Labs, Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-05 and not restated since.
Healthcare

Scale

Market cap
$303m
Revenue TTM
$10m
Net income TTM
$-94m
Free cash flow
$-88m
Composite score
—
Sector rank
#2611

Valuation

P / E
—
EV / EBITDA
—
EV / sales
-1.5
FCF yield
-29.04%
Yield vs 10-yr
-36.43pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-912.2%
EBITDA margin
—
ROE
-25.2%
ROIC
-189.2%
Revenue growth
—

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

For example, we are party to the Sales Agreement with Leerink relating to the sale and issuance, from time to time, of shares of our common stock in at-the-market equity offerings with an aggregate offering price up to $75.0 million.BioAge Labs, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →